HCV CENTER STUDIES ON INFECTIOUS HCV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 大约2%的美国人口长期感染丙型肝炎病毒(丙型肝炎病毒)。在大约20%的感染者中，慢性丙型肝炎病毒感染会导致严重的肝脏疾病，包括肝硬变和肝癌。目前的干扰素和利巴韦林治疗在大多数病例中不能导致病毒清除。在分子水平上更好地了解丙型肝炎病毒的复制，以及决定感染是否会发展为慢性感染或病毒清除的因素，对于改进抗病毒策略的发展至关重要。这些研究对疫苗和抗病毒药物的开发都很重要。这是东南部合作的HEPATTIS C研究小组(0024)的分包合同。其目标是测试在组织培养中复制的丙型肝炎病毒的分子克隆，以便在黑猩猩身上复制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Approximately 2% of the US population in chronically infected with hepatitis C virus (HCV). Chronic HCV infections result in significant liver disease including cirrhosis and liver cancer in approximately 20%of infected individuals. The current therapy of interferon and ribavirin does not result in viral clearance in the majority of cases. A better understanding of the replication of HCV at a molecular level as well as the factors that determine whether an infection will proceed to chronic infection or viral clearance are essential for the development of improved antiviral strategies. These studies are important for both vaccine and antiviral development. This is subcontract from the SOUTHEASTERN COOPERATIVE HEPATTIS C RESEARCH GROUP (0024). The goal was to test a molecular clone of HCV that replicates in tissue culture for replication in chimpanzees.